Oklahoma City, OK (May 8, 2020) – The law firm of Federman & Sherwood has initiated an investigation into CytoDyn Inc. [OTC: CYDY] and its officers and directors, with respect to possible violations of federal securities laws. On April 27, 2020, CytoDyn, a late-stage biotechnology company, issued a press release indicating it had submitted a “Biologics License Application (“BLA”) to the U.S. Food and Drug Administration for Leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients.” On May 7, 2020, CytoDyn announced that its BLA for Leronlimab “will be considered completed after the clinical datasets are submitted on May 11, 2020.”
If you purchased shares of common stock and suffered a loss on that investment in CytoDyn Inc., please complete the following Investor Certification. [contact-form-7 id=”1524″ title=”CytoDyn Inc. (OTC: CYDY) Investor Certification”]
If you have any information to assist in our investigation or have questions or concerns regarding this notice or your rights or interests in this matter, or you may contact William B. Federman with any questions you may have regarding this investigation. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.